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Spastin, the most commonly mutated protein in the autosomal dominant form of hereditary spastic paraplegia (AD-
HSP) has been suggested to be involved in vesicular cargo trafﬁcking; however, a comprehensive function of spastin has
not yet been elucidated. To characterize the molecular function of spastin, we used the yeast two-hybrid approach to
identify new interacting partners of spastin. Here, we report ZFYVE27, a novel member of the FYVE-ﬁnger family of
proteins, as a speciﬁc spastin-binding protein, and we validate the interaction by both in vivo coimmunoprecipitation
and colocalization experiments in mammalian cells. More importantly, we report a German family with AD-HSP inwhich
ZFYVE27 (SPG33) is mutated; furthermore, we demonstrate that the mutated ZFYVE27 protein shows an aberrant intra-
cellular pattern in its tubular structure and that its interaction with spastin is severely affected. We postulate that this
speciﬁc mutation in ZFYVE27 affects neuronal intracellular trafﬁcking in the corticospinal tract, which is consistent with
the pathology of HSP.
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Impaired axonal transport has been implicated in many
neurodegenerative disorders. One such group of neurode-
generative disorders that primarily affects lower limbs is
hereditary spastic paraplegia (HSP). HSPs are characterized
by progressive spastic paralysis of the legs, usually caused
by length-dependent distal degeneration of the cortico-
spinal tract axons.1 Clinically, HSPs are classiﬁed as either
the pure or the complex form.2 In the pure form of HSP,
spastic paraplegia occurs in relative isolation and is often
accompanied by urinary urgency. The complex form of
HSP is associated with additional neurological or nonneu-
rological features. HSPs are genetically complex: autoso-
mal dominant, recessive, and X-linked modes of inheri-
tance are reported for both pure and complexHSP.2Within
each inheritance pattern group, there is further locus het-
erogeneity. For autosomal dominant HSP (AD-HSP), 13 dif-
ferent loci are reported; also, 13 loci for the autosomal re-
cessive form and 3 loci for the X-linked disease are known.
It is likely thatmore loci will be identiﬁed in the near future.
Eleven of the HSP genes are now identiﬁed. However, mu-
tation in spastin (MIM 604277) is the most common cause
of HSP and accounts for up to 40% of AD-HSP cases.3–6
Spastin is a member of the AAA family of proteins and
is ubiquitously expressed in all tissues. The AAA proteins
are proven or putative ATPases, and they are characterized
by a conserved C-terminal domain containing one or two
AAA cassettes.7 The N-terminal domain of the protein,
which contains recognition sites for substrates or adap-
tors, is highly divergent and, therefore, confers speciﬁcity
to its cellular function.8
A comprehensive function of spastin is not yet eluci-
dated; previous reports suggested that spastin is princi-
pally involved in microtubule dynamics and severing.9–11
However, the expression of spastin in punctate vesicles in
cultured cells also suggests a role in vesicular trafﬁcking,
which is now supported by emerging reports.12,13 Further-
more, the N-terminal portion of spastin contains a micro-
tubule-interacting and trafﬁcking (MIT) domain, which is
predicted to play a role in the endosomal trafﬁcking pro-
cess.14 The MIT domain corresponds to a slightly extended
version of the End13-SNX15-Pa1B (ESP) homologydomain,
which is also present in VPS4, SKD1, RPK118, and SNX15,
all of which have a well-established role in endosomal
trafﬁcking.15–18
Spastin is a multifaceted protein, and, to elucidate its
function, we performed a yeast two-hybrid assay. In our
screen, we used spastin-lacking exon 4 (GenBank acces-
sion number NM_199436) (referred to as “spastin”) as bait
against a human brain cDNA library and tested 62.2# 10
clones. This spastin splice variant is the major transcript in
adult spinal cord and could be pathologically relevant.19
Stringent screening revealed that 31 clones were able to
grow in selective media and were also positive for a-ga-
lactosidase activity (data not shown). Sequencing of these
clones led to the identiﬁcation of seven ORFs of ﬁve unique
genes (table 1). Clone 18,whichwas identiﬁed as apotential
spastin-interacting protein, encodes for ZFYVE27 and con-
tains the C-terminal fragment of ZFYVE27 (amino acids
209–318) and the 3′ UTR, which corresponds to nucleo-
tides 822–2746 of the ZFYVE27 cDNA (ZFYVE27-c isoform
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Table 1. Genes Identiﬁed as Putative
Spastin-Interacting Proteins in our Yeast
Two-Hybrid Assay
Clonea Geneb
Chromosomal
Locationc
Amino
Acidsd
3 Reticulon3 11q13 57–236
5 CRELD5 3p25.2 201–421
6 COPS5 8q13.2 67–335
8 Reticulon1 14q23.1 632–776
10 Reticulon1 14q23.1 632–776
18 ZFYVE27 10q24.2 209–319
22 Reticulon3 11q13 85–236
a Identity of the clone designated in our yeast two-
hybrid experiment.
b Name of the gene corresponding to the clone.
c Chromosomal location of the gene.
d Encoding amino acid sequence present in the
clone.
Figure 1. Spliced isoforms of ZFYVE27. The legend is available
in its entirety in the online edition of The American Journal of
Human Genetics.
[GenBank accession number AK097945]). ZFYVE27 is a
novel protein that belongs to the FYVE-ﬁnger family of
proteins. The FYVE-ﬁnger domain is suggested to be re-
sponsible for endosomal localization of these proteins,
and the majority of the FYVE-ﬁnger proteins serve as reg-
ulators of endocytic membrane trafﬁcking.20,21 The fact
that ZFYVE27 is a putative endosomal protein, combined
with the recent ﬁnding of spastin interaction with en-
dosomal protein CHMP1B,12 prompted us to investigate
the interaction of ZFYVE27 with spastin and its physio-
logical relevance.
In the Ensembl database, four different splice variants
of ZFYVE27 are reported, as shown in ﬁgure 1A. To amplify
the complete ORF of ZFYVE27, we performed RT-PCR on
human brain RNA with a primer pair ﬂanking the com-
plete ORF of the transcripts, and we were able to amplify
a single ∼1-kb product (ﬁg. 1B). Sequencing revealed that
this product corresponds to the variant form, ZFYVE27-c
(ﬁg. 1A). We used this ZFYVE27-c product in our further
investigations and referred to it as “ZFYVE27.”
To determine the intracellular distribution of ZFYVE27,
we generated epitope-tagged ZFYVE27 constructs.Analysis
of cells, which were transfected with E2-ZFYVE27 or green
ﬂuorescent protein (GFP)–ZFYVE27 construct, showed that
ZFYVE27 is predominantly expressed in punctate vesicles
(ﬁg. 2A and 2B). However, in a small proportion of cells,
a tubular pattern of expression was also observed (ﬁg. 2C).
Overall, the intracellular distribution of ZFYVE27 in punc-
tate vesicles was comparable to the expression pattern re-
ported for other well-characterized members of the FYVE-
ﬁnger family of proteins.22–24 Colocalization studies with
subcellular markers revealed an overlapping expression
with the endosomal marker, EEA122,23 (ﬁg. 2D–2F), and the
endoplasmic reticulum (ER) marker, RTN125,26 (ﬁg. 2G–2I).
ZFYVE27 expression in the vesicles originating from both
ER and endosome could be dependent on the metabolic
stage of the cell after the transient transfection. Presum-
ably, the biogenesis of ZFYVE27 occurs in ER, and then it
could be sorted to the endosome through its FYVE-ﬁnger
domain interaction with the endosomal membrane. Ex-
amination of HeLa cells coexpressing GFP-ZFYVE27 and
c-Myc-spastin by immunoﬂuorescence microscopy re-
vealed an obvious colocalization in vesicular-like struc-
tures in the cytoplasm (ﬁg. 2J–2L). The colocalization of
ZFYVE27 and spastin in discrete vesicles in the cytosol
also highlights the physiological interactionbetween spas-
tin and ZFYVE27.
To investigate the interaction of ZFYVE27 with spastin,
we performed coimmunoprecipitation studies by cotrans-
fecting NIH 3T3 cells with E2-ZFYVE27 and c-Myc-spastin
constructs. When E2-ZFYVE27 was immunoprecipitated
from total protein lysate of the transfected cells, c-Myc-
spastin (64 kDa) could also be detected in the precipitated
fraction (ﬁg. 3A). Similarly, E2-ZFYVE27 (42 kDa) could be
coimmunoprecipitated with c-Myc-spastin (ﬁg. 3B). To
determine the domain of spastin, which is responsible for
the interaction, we generated N-terminal (c-Myc-spas-
tinDNT) and C-terminal (c-Myc-spastinDAAA) deletion
constructs of spastin for immunoprecipitation experi-
ments. The c-Myc-spastinDNT lacks the ﬁrst 300 amino
acids, including the MIT domain, whereas, in the c-Myc-
spastinDAAA construct, amino acids 398–583 were deleted.
Our results revealed that E2-ZFYVE27 was able to inter-
act with c-Myc-spastinDAAA (ﬁg. 3C) but not with c-Myc-
spastinDNT (data not shown), suggesting that spastin me-
diates interaction with ZFYVE27 through its N-terminal
domain, which consists of a MIT motif. Interestingly, the
N-terminal spastin domain is also responsible for the in-
teraction with other proteins—for example, the endoso-
mal protein CHMP1B,12 microtubules,9 and the centro-
somal protein NA14.27 To validate the interaction between
spastin and ZFYVE27 at the endogenous level, we per-
formed an immunoprecipitation assay, using antispastin
antibodies with protein extract derived from HeLa cells
transfected with E2-ZFYVE27. Our analysis conﬁrmed that
endogenous spastin interacts with E2-ZFYVE27 (ﬁg. 3D).
The fact that ZFYVE27 is a spastin-interacting protein
and its expression in brain led us to consider ZFYVE27 as
a candidate gene for HSP. The ZFYVE27 gene is located
on chromosome 10q24.2 and consists of 13 exons. We
investigated genomic DNA of 43 patients with AD-HSP for
mutation in ZFYVE27 (for primer sequences, see table 2).
Ourmutational analysis detected a single sequence variant
in the exon 6 of ZFYVE27 in the genomic DNA of one
patient with AD-HSP (III.2 in ﬁg. 4B).We identiﬁed a trans-
version, GrT, at position 572 of ZFYVE27 cDNA (ZFYVE27-
a isoform [GenBank accession number NM_001002261]),
Figure 2. Intracellular distribution of ZFYVE27 and colocalization with endosomal marker (EEA1), ER marker (RTN1), and spastin in
mammalian cells. HeLa cells were transiently transfected with either E2-tagged ZFYVE27 or GFP-ZFYVE27 constructs. A, E2-tagged ZFYVE27
expressed in the punctate vesicles distributed in the cytoplasm. B, GFP-ZFYVE27 also showing vesicular expression in the cytosol. C, A
small proportion of cells revealing a tubular pattern of expression, which seems to arise from the perinuclear region and is then
distributed in the peripheral region of the cytoplasm. D–F, HeLa cells transiently transfected with GFP-ZFYVE27 and immunostained
with EEA1. D, HeLa cell expressing GFP-ZFYVE27 in cytoplasmic vesicles. E, Staining of the same cell, with EEA1 antibody showing
expression in punctate vesicles in the cytoplasm. F, Subset of cytoplasmic vesicles showing coexpression of GFP-ZFYVE27 and EEA1, as
observed in the superimposed image. The nuclei of the cells were stained with 4′,6-diamidino-2-phenylindole (DAPI). G–I, Colocalization
of GFP-ZFYVE27 and ER marker, E2-RTN1, in the HeLa cells. G, GFP-ZFYVE27; H, E2-RTN1; I, overlay image. An overlapping expression
pattern in vesicular structure around the perinuclear region can be seen between GFP-ZFYVE27 and E2-RTN1 in the cytoplasm. J-L,
Expression of GFP-ZFYVE27 and c-Myc-spastin. J, GFP-ZFYVE27; K, c-Myc-spastin; L, overlay image. A striking level of colocalization
between GFP-ZFYVE27 and c-Myc-spastin can be observed in cytoplasmic vesicles. Scale bar is 20 mm.
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Table 2. Primer Sequences for Amplifying
and Sequencing of ZFYVE27
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 3. In vivo interaction between spastin and ZFYVE27 in mammalian cells. NIH 3T3 cells were cotransfected with c-Myc-spastin
and E2-ZFYVE27 constructs. Soluble protein lysate was prepared after 24–48 h of transfection. A, Immunoprecipitation performed with
E2-tag antibody, and, subsequently, Western blot performed with c-Myc antibody. Lane 1, standard protein lysate, which serves as a
control for transfection efﬁciency; lane 2, immunoprecipitated fraction; lane 3, mock precipitation done without E2-tag antibody. A
64-kDa band corresponding to c-Myc-spastin can be seen in lane 1 and lane 2 but not in lane 3. B, Precipitation done with c-Myc
antibody and the immunoblot done with E2 antibody. A 42-kDa band corresponding to E2-ZFYVE27 can be detected in protein standard
(lane 1) and precipitated fraction (lane 2) but not in mock experiment (lane 3). C, Precipitation performed with cells cotransfected
with c-Myc-spastinDAAA, E2-ZFYVE27 with E2 antibody, and the Western blot with c-Myc antibody. A c-Myc-spastinDAAA protein can
be detected as a 41-kDa band in the precipitated fraction (lane 1) as well as in the standard protein fraction (lane 2) but not in the
mock precipitate (lane 3). D, Immunoprecipitation assay between endogenous spastin and E2-ZFYVE27, with the use of antispastin
antibody. Lane 1, immunoprecipitated fraction; lane 2, protein standard; lane 3, mock precipitation. The endogenous spastin was able
to coprecipitate E2-ZFYVE27, since, in the immunoblot, a 42-kDa band corresponding to E2-ZFYVE27 could be detected in both lanes
1 and 2 with the use of E2 antibody.
which leads to a missense mutation, G191V, in the protein
(ﬁg. 4A). Sequencing of the ZFYVE27 gene in the genomic
DNA of other family members (IV.2, IV.3, and IV.4) re-
vealed that the mutation c.572GrT (p.G191V) segregated
with the clinical phenotype in the affected individuals
(IV.2 and IV.3) and was not detected in the clinically un-
affected individual (IV.4) (ﬁg. 4B). An extensive GenBank
search of ZFYVE27 EST clones for the presence of this base
exchange failed to detect any EST containing the identi-
ﬁed sequence variant. Furthermore, this mutationwas not
found in 210 control chromosomes (data not shown).Thus,
the detected base exchange is, most probably, causative for
the HSP in this family and is not a rare polymorphism.
The clinical features of the affected members suggest
that theirs is a pure form of HSP. The index patient, III.2,
had had pes equinus for many years when she noticed a
gait disorder at age 50 years. She then manifested hyper-
reﬂexia and spasticity of the lower limbs, a positive Ba-
binski sign for an ankle clonus. Sensitivity was normal.
Six years ago, she needed walking sticks, some years later
a wheelchair was necessary, and now she is bedridden.
Her daughter (IV.2), aged 47 years, also had pes equinus
for many years. Five years ago, she developed a gait dis-
order. She also has hyperreﬂexia and spasticity of the legs,
as well as an ankle clonus. The index patient’s son (IV.3)
is reported to have pes equinus, spasticity of the legs, and
a gait disorder. However, the deﬁnite age of onset of the
symptoms could not be determined from the family his-
tory. Cognitive deﬁcits or additional neurological symp-
toms are not present in this family. Thus, this SPG form
seems to be a pure form of HSP.
ZFYVE27 is located at 10q24.2. In the vicinity of this
locus, two SPG loci were previouslymapped—namely, SPG9
(MIM 601162), which is located between 10q23.3 and
10q24.2,28 and SPG27 (MIM 609041), which is mapped
within 10q22.1-q24.1.29 ZFYVE27 could be excluded as a
candidate gene for SPG27 subtype, sinceZFYVE27 is located
distal to the critical region of the locus. Recent updated
mapping of the SPG9 locus (M. Seri, personal communi-
cation) also excluded ZFYVE27 from the reﬁned region.
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Figure 4. Identiﬁcation of a mutation in the ZFYVE27 gene in a family with AD-HSP. A, Forward sequence of a PCR product of exon
6 of the ZFYVE27 gene in genomic DNA from an affected patient and a control. The mutated nucleotide is indicated by a black arrow;
the identiﬁed mutation GrT leads to the amino acid substitution G191V in ZFYVE27. B, Pedigree of a ﬁve-generation German family
with AD-HSP, showing segregation of G191V in affected family members. We could not assert whether individual II.1 was symptomatic,
because of limited family history.
Figure 5. In silico analysis of the ZFYVE27 mutation. The legend
is available in its entirety in the online edition of The American
Journal of Human Genetics.
Therefore, the ZFYVE27 locus should be considered a new
subtype of HSP, which we termed “SPG33.”
The identiﬁed mutation G191V of ZFYVE27 isoform-a
(position G105V of isoform-c) is located near the vicinity
of the third transmembrane (TM) motif. In silico topology
prediction, with the use of SOSUI software, revealed that
the G105V mutation shifts the TM motif forward by three
amino acids (ﬁg. 5A), which could have a conformational
effect in the three-dimensional structure of ZFYVE27, par-
ticularly on the FYVE-ﬁnger domain. Phylogenetic anal-
ysis revealed that the G105 residue of ZFYVE27-c is con-
served inmost vertebrates (ﬁg. 5B). To study the functional
implication of the G105V exchange mutation on the
ZFYVE27 protein, we introduced thismutation in theGFP-
ZFYVE27 construct and performed in vivo immunopre-
cipitation assay. We used c-Myc antibody to precipitate
spastin from the protein lysate derived from cells cotrans-
fected with c-Myc-spastin and GFP-ZFYVE27(G105V). Im-
munoblot analysis with GFP antibody detected either no
band (ﬁg. 6A, panel i) or, by sample overloading, a very
weak band (ﬁg. 6A, panel ii) equivalent to protein size of
GFP-ZFYVE27(G105V). The ZFYVE27 interacts with spas-
tin through its C-terminal domain, and the G105V mu-
tation could lead to misfolding of the C-termini of the
FYVE-ﬁnger domain, which could be consequential to this
interaction.
Next, we investigated the effect of this mutation on the
intracellular distribution of ZFYVE27 protein. Analysis of
the transfected cells by ﬂuorescence microscopy indicated
that, in addition to diffuse vesicular expression (ﬁg. 6B),
a signiﬁcant proportion of cells showed expression in tu-
bular structures or in plasma membrane (ﬁg. 6C–6D). Ex-
amination of cells coexpressing GFP-ZFYVE27(G105V)
and c-Myc-spastin by immunoﬂuorescencemicroscopy re-
vealed weak and diffuse colocalization in a subset of ves-
icles in the cytoplasm (ﬁg. 6E–6G). The observation that
a signiﬁcant proportion of cells showed a tubular expres-
sion, presumably in the ER network, suggests that the
G105V mutation might hinder or delay the biogenesis
process of ZFYVE27.
Our genetic and biochemical studies strongly suggest
that the G105V mutation in ZFYVE27 is responsible for
the pathological phenotype observed in this family with
AD-HSP. It is unclear whether this mutation results in a
loss-of-function or a dominant-negative form of ZFYVE27
that is due to misfolding of the C-terminal FYVE-ﬁnger
domain. Defects in the spastin–dependent/independent
endosomal transport may inﬂuence the retrograde trans-
mission and, therefore, contribute to a slow accumulation
of pathological processes/substrates in HSP. Identiﬁcation
of ZFYVE27 as a mutated gene in HSP, therefore, will aid
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Figure 6. Functional analysis of the ZFYVE27 mutation. A, Immunoprecipitation assay between c-Myc-spastin and GFP-ZFYVE27(G105V),
with the use of anti-Myc antibody and detection with anti-GFP antibody. Lane 1, Immunoprecipitated fraction; lane 2, protein standard;
lane 3, mock precipitation. No band (i) or a very weak band (ii) corresponding to GFP-ZFYVE27 was detected in the precipitated fraction.
B–G, Subcellular localization of GFP-ZFYVE27(G105V) and coexpression with c-Myc-spastin in HeLa cells. B, Transiently transfected HeLa
cells showing a diffuse vesicular expression. However, a signiﬁcant proportion of cells showed expression in tubular structures arising
from the perinuclear region. C, GFP-ZFYVE27(G105V) localized to tubular structure in the cytoplasm. D, GFP-ZFYVE27(G105V) showing
expression also in the plasma membrane. E–G, Coexpression of c-Myc-spastin and GFP-ZFYVE27(G105V) in HeLa cells showing a diffuse
overlapping pattern of expression. E, GFP-ZFYVE27(G105V); F, c-Myc-spastin; G, superimposition of images E and F. Scale bar is 20 mm
(B–G).
in the understanding of the axonal neurodegeneration in
HSP and suggests that other molecules involved in this
process may play a role in the pathogenesis of this group
of diseases. Moreover, by elucidating the molecular mech-
anism and by studying the interacting partner(s) for known
HSP proteins, novel genes involved in HSP pathogenesis
might be identiﬁed. More insight into the pathological
mechanisms will help to create new therapeutical options
for patients with HSP in the future.
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